January 2025- Pulse Biosciences, inc. announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.

“We are thrilled to have Paul assume the role of Chief Executive Officer,” said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. “Having worked very closely with Paul, we have established a strong working relationship and have realized our visions for the future of Pulse closely align. His impressive track record and network in the medical technology space spans decades and is a testament to his ability to lead organizations and create value. Particularly, Paul’s experience scaling global franchises across multiple clinical specialties and driving the adoption of innovative technologies will now be an even greater asset for Pulse moving forward.”

Also Read : TruBridge Names Merideth Wilson as Financial Health General Manager

Paul LaViolette has significant experience as a large-scale operator at global healthcare corporations as well as a leader to a diverse group of innovative medical technology startups as a venture investor and board member. As a Managing Partner at SV Health Investors, Paul invested in numerous portfolio companies and remains active on the Board of Directors of certain SV Health Investors portfolio companies. Before his investing career, he served in various executive capacities at Boston Scientific Corporation for 15 years, including as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. Prior to Boston Scientific, he also served as President, Cardiology, for CR Bard and various marketing roles at Kendall (Medtronic).

“I believe nano-PFA is a remarkable advance in medical technology and will make a profound impact on healthcare for the benefit of countless patients and providers,” said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. “The established team, innovative technologies and portfolio of therapies under development attracted me to Pulse. Having now worked with Bob and the team, I am thrilled to take on this role and cannot wait to contribute to the Company’s continued success.”